First-in-human Study of Mivebresib (ABBV-075), an Oral Pan-inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
CONCLUSIONS: Based on safety and tolerability, mivebresib RP2D is 1.5mg for the daily schedule, 2.5mg for 4/7 and 3mg for M-W-F. Mivebresib has a tolerable safety profile and stable disease was observed in some patients with malignant solid tumors. PMID: 31420359 [PubMed - as supplied by publisher]
Abstract Inhaled pulmonary vasodilators are a powerful tool in the arsenal of therapies designed to treat pulmonary hypertension in pediatrics. Yet only 1 inhaled vasodilator, inhaled nitric oxide (INO), has been approved by the Food and Drug Administration for use in neonates> 34 weeks gestational age with persistent pulmonary hypertension of the newborn. Off-label use of inhaled vasodilators is common in the neonatal and pediatric population despite a lack of evidence. Growing focus on providing evidence-based therapies combined with the increasing cost of INO has led to the exploration of other inhaled pulmo...
Abstract The purpose of this study was to evaluate the diagnostic performance of magnetic resonance (MR) radiomics-based machine learning algorithms in differentiating squamous cell carcinoma (SCC) from lymphoma in the oropharynx. MR images from 87 patients with oropharyngeal SCC (n=68) and lymphoma (n=19) were reviewed retrospectively. Tumors were semi-automatically segmented on contrast-enhanced T1-weighted images registered to T2-weighted images, and radiomic features (n=202) were extracted from contrast-enhanced T1- and T2-weighted images. The radiomics classifier was built using elastic-net regularized genera...
Abstract PURPOSE: Thrombocytopenia (platelet count
CONCLUSION: In real-world practice, pembrolizumab was feasible and effective in heavily treated recurrent gynecologic cancer patients with poor performance status who may not be eligible for enrollment in clinical trials. PMID: 32975058 [PubMed - in process]
Publication date: January 2021Source: Materials Science and Engineering: B, Volume 263Author(s): Nazire Altunkök, Özlem Biçen Ünlüer, Ebru Birlik Özkütük, Arzu Ersöz
PMID: 32976145 [PubMed - as supplied by publisher]
Publication date: Available online 25 September 2020Source: Biosensors and BioelectronicsAuthor(s): Roberta D'Agata, Noemi Bellassai, Matteo Allegretti, Andrea Rozzi, Saša Korom, Alex Manicardi, Elisa Melucci, Edoardo Pescarmona, Roberto Corradini, Patrizio Giacomini, Giuseppe Spoto
Publication date: Available online 26 September 2020Source: Saudi Journal of Biological SciencesAuthor(s): Padmini Rajendran, Uma Maheshwari Nallal, Saravanan Parameswaran, Keun Woo Lee, Razia Muthuswamy, Mona S Alwahibi, B. Ravindran, Mohamed Soliman Elshikh, Young Ock Kim, Hyungsuk Kim, Hak-Jae Kim
Publication date: Available online 14 September 2020Source: Life Sciences in Space ResearchAuthor(s): Luana Hafner, Linda Walsh, Uwe Schneider
Chem. Commun., 2020, Accepted Manuscript DOI: 10.1039/D0CC04957C, CommunicationMizuho Yasuda, Yue Ma, Sachiko Okabe, Yuki Wakabayashi, Dongdong Su, Young-Tae Chang, Hiroyuki Seimiya, Masayuki Tera, Kazuo Nagasawa Macrocyclic hexaoxazoles (6OTDs) are G-quadruplex (G4) ligands, and some derivatives, such as L2H2-6OTD (1a) bearing two aminobutyl side chains, show cytotoxicity towards cancer cells. To identify the cellular target of... The content of this RSS Feed (c) The Royal Society of Chemistry